MIA

Around the World in 114 Days with Princess Cruises!

Retrieved on: 
Thursday, May 2, 2024
Circle, Sale, Circumnavigation, Wine, Princess, MIA, FLL, Coral Princess, Love, Wi-Fi, LAX, History, Princess Cruises, UNESCO, World Heritage Site, Tourism

SANTA CLARITA, Calif., May 2, 2024 /PRNewswire/ -- Princess Cruises today announced its 2026 World Cruise - a 114-day voyage aboard Coral Princess - will visit 52 ports in 28 countries, across six continents, the most destinations ever reached on a Princess World Cruise. With itineraries now on sale, global-seeking cruisers can take advantage of early booking perks and secure their spot now aboard the 114-day adventure that will sail over 35,000 nautical miles.

Key Points: 
  • SANTA CLARITA, Calif., May 2, 2024 /PRNewswire/ -- Princess Cruises today announced its 2026 World Cruise - a 114-day voyage aboard Coral Princess - will visit 52 ports in 28 countries, across six continents, the most destinations ever reached on a Princess World Cruise.
  • New elements guests can look forward to aboard the 2026 Princess World Cruise include:
    Inaugural call to Boracay, a tropical paradise in central Philippines known for its gorgeous beaches and resorts, a first for Princess.
  • Coral Princess will also make first-time World Cruise calls to:
    Visits to 52 destinations, the most ever offered on a Princess World Cruise, with access to 45 UNESCO World Heritage Sites around the globe.
  • More information, including the full and segmented 2026 World Cruise itineraries, can be found at http://www.princess.com/worldcruise .

XWELL, Inc. Reports Fiscal Year 2023 Results

Retrieved on: 
Tuesday, April 16, 2024
Digital, Hydro massage, The Company, Partnership, Webcast, Face, GAAP, CXM, WalletHub, CDC, Massage, Wellness, Audit committee, Airport, TGS, Annual report, Pennsylvania Station, Abu Dhabi International Airport, MIA, Health, Heart, Collection, Skin care, Hair removal, Beauty, Genomics, SARS-CoV-2, Traveler, Acquisition, Form 10-K, Bank statement, Growth, Airline

The Company reported an operating loss for 2023 of approximately $28.2 million versus an operating loss of $31.2 million in 2022.

Key Points: 
  • The Company reported an operating loss for 2023 of approximately $28.2 million versus an operating loss of $31.2 million in 2022.
  • Additionally, beginning in third quarter of 2023, the Company began reporting operating results for HyperPointe within its XpresTest business.
  • Total revenue during fiscal year ended December 31, 2023, was $30.1 million compared to $55.9 million in the prior year.
  • The operating loss for 2023 was approximately $28.2 million compared with an operating loss of approximately $31.2 million in 2022.

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Retrieved on: 
Tuesday, April 9, 2024
BID, Patient, Fluorouracil, 3D, MIA, Cancer, AACR, TGI, Pancreatic cancer, Paclitaxel, TGA, Annual general meeting, Medical imaging

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.

Key Points: 
  • “We are evaluating a broad range of combinations for a variety of cancer types in our humanized 3D tumor growth assays, together with animal models.
  • The data we are sharing today at AACR clearly demonstrates IMM-1-104’s potential in combination with chemotherapy for pancreatic cancer.
  • IMM-1-104 showed promising combination effects when treated with gemcitabine (GEM), paclitaxel (PAC) or fluorouracil (5FU) in 3D-tumor growth assay (TGA) pancreatic cancer models.
  • IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer.

TWISTED TEA HARD ICED TEA UNVEILS GAME-CHANGING TWIST FOR GOLFERS: CHEATER PANTS

Retrieved on: 
Tuesday, April 2, 2024
Golf, Boston Beer Company, Tea, Freedom, ABV, Leg, MIA

Boston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Twisted Tea Hard Iced Tea, the masterminds behind everyone's favorite hard iced tea, is shaking up the golf world with its newest creation: Twisted Tea Cheater Pants.

Key Points: 
  • Boston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Twisted Tea Hard Iced Tea, the masterminds behind everyone's favorite hard iced tea, is shaking up the golf world with its newest creation: Twisted Tea Cheater Pants.
  • Like any pair of golf pants, Twisted Tea Cheater Pants have pockets.
  • Once you sink it, crack open an ice-cold Twisted Tea to celebrate— it's tea time on the green!
  • A golf essential, Twisted Tea kicks the fun up a notch with real tea flavor and 5% ABV.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, March 14, 2024
Nucleus, Bone marrow, BCMA, BioNTech, B-ALL, Patient, ALL, SLE, Engineering, Minocycline, European Medicines Agency, Therapy, Research, Canadian Aviation Regulations, Flow cytometry, ASH, General counsel, Immunotherapy, SVP, EMA, Legal Affairs, Trial of the century, GMP, SME, BLA, Nature Communications, Development, UCL, Biologics license application, Multiple myeloma, MIA, University College London, Senior, TRBC, GD2, ASCO, FDA, CD19, Conference call, Conference, MAA, EHA, ADS, MHRA, T cell, ACS Chemical Biology, PDUFA, Autoimmune disease, Pharmaceutical industry

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Retrieved on: 
Tuesday, March 12, 2024
Certification, Nucleus, Patient, Orphan, ALL, MIA, EMA, GMP, MHRA, Therapy, Priority, FDA, Pharmaceutical industry

This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024.

Key Points: 
  • This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024.
  • Following a full site inspection in February 2024, Autolus’s Nucleus site has recently received the formal certification from the MHRA.
  • The MHRA issued two new licenses to cover both clinical and commercial manufacture from the site and found no major or critical observations in their summary report.
  • Our manufacturing team did an outstanding job qualifying, validating and taking into operation the Nucleus in record time and establishing the foundation for high quality product supply,” commented Dave Brochu, Chief Technology Officer of Autolus.

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, DNA, MIA, Bacteria, SARS-CoV-2, RSV, Ginkgo Bioworks, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Federal, Vaccine

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • Since its inception in September 2021, the TGS program has demonstrated its ability to serve as an early detection mechanism for new pathogens and fill gaps in global biosurveillance.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • “We are thrilled to have the opportunity to take the TGS program to the next level.

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
O'Hare International Airport, Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, Public, DNA, Bacteria, MIA, SARS-CoV-2, RSV, Ginkgo Bioworks, Federal, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Vaccine

BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • We are honored that CDC continues to trust this consortium to deliver a strategic piece of our biothreat preparedness."
  • "The additional funding of the program allows us to add infrastructure to support new mobile testing centers at Miami International Airport and Chicago O'Hare International Airport.

EQS-News: fox e-mobility AG announces preliminary figures for the 2022 financial year and provides information on current activities

Retrieved on: 
Wednesday, March 13, 2024
MIA, Supervisory board, VDL, Marketing, FSS, News, NDA, Partnership, Security (finance)

So far, fox e-mobility has not generated any revenue from vehicle sales as the company is still in the development phase.

Key Points: 
  • So far, fox e-mobility has not generated any revenue from vehicle sales as the company is still in the development phase.
  • The publication of the complete and audited annual financial statements for the 2022 financial year is expected by April 30, 2024 latest.
  • The company will announce preliminary figures for the key financial data for the 2023 financial year in the upcoming week.
  • Since the resignation of Supervisory Board member Russell Pfeiffer on February 8, 2022, the Supervisory Board has only had three members.

Q2 Metals Concludes Its 2024 Winter Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada

Retrieved on: 
Tuesday, February 27, 2024
Lithium, Diamond, Lady, Quality control, MIA, News, LIBS, Suite (music), QA/QC, Figure, Mia, Quality assurance, Table, National instrument, PDAC, Metal, Online shopping

Vancouver, BC, Feb 27, 2024 - (ACN Newswire) - Q2 Metals Corp. (TSXV: QTWO) (OTCQB: QUEXF) (FSE: 458) ("Q2" or the "Company") is pleased to announce it has concluded its winter 2024 drill program ("Winter Drill Program") at its wholly owned, 8,668-ha Mia Lithium Property (the "Property") located in the Eeyou Istchee James Bay Territory of Quebec.

Key Points: 
  • Vancouver, BC, Feb 27, 2024 - (ACN Newswire) - Q2 Metals Corp. (TSXV: QTWO) (OTCQB: QUEXF) (FSE: 458) ("Q2" or the "Company") is pleased to announce it has concluded its winter 2024 drill program ("Winter Drill Program") at its wholly owned, 8,668-ha Mia Lithium Property (the "Property") located in the Eeyou Istchee James Bay Territory of Quebec.
  • "The winter drill program at the Mia Property has confirmed the spodumene mineralized pegmatite at the western end of the Mia Trend," commented Q2 Metals VP Exploration, Neil McCallum.
  • A total of 20 drill holes were completed on the Mia Trend for approximately 3,085 Metres (Figure 1).
  • A total of 9 additional drill holes were completed along the remainder of the more than 10-kilometre-long Mia Trend.